Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
04 Apr 2025
// REUTERS
https://www.reuters.com/business/putin-names-little-known-firm-run-pharma-company-spun-off-germanys-stada-2025-04-04/
18 Mar 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/stada-says-still-considering-all-options-after-report-delayed-ipo-2025-03-18/
28 Aug 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/germanys-stada-reports-rosy-earnings-first-half-2024-ceo-tempers-sales-rumors
22 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/22/2916396/0/en/STADA-and-Alvotech-launch-Uzpruvo-the-first-approved-ustekinumab-biosimilar-to-Stelara-across-Europe.html
12 Jun 2024
// PRESS RELEASE
https://investors.alvotech.com/news-releases/news-release-details/alvotech-and-stada-add-strategic-alliance-through-denosumab
31 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/calliditas-partner-stada-receives-positive-chmp-opinion-recommending-full-approval-for-kinpeygo-for-the-treatment-of-iga-nephropathy-302159841.html
Details:
Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Immunology Brand Name: Uzpruvo
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Alvotech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 01, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Alvotech
Deal Size : Inapplicable
Deal Type : Inapplicable
STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar
Details : Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Product Name : Uzpruvo
Product Type : Antibody
Upfront Cash : Inapplicable
October 01, 2024
Details:
Kinpeygo (budesonide)is a modified-release capsule, glucocorticoid receptor agonist, which is indicated for the treatment of patients with primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Kinpeygo
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2024
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas’ STADA Receives EC Decision for Full Approval of Kinpeygo® in IgA Nephropathy
Details : Kinpeygo (budesonide)is a modified-release capsule, glucocorticoid receptor agonist, which is indicated for the treatment of patients with primary IgA nephropathy.
Product Name : Kinpeygo
Product Type : Steroid
Upfront Cash : Inapplicable
July 26, 2024
Details:
Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Immunology Brand Name: Uzpruvo
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Alvotech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Alvotech
Deal Size : Inapplicable
Deal Type : Inapplicable
STADA and Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar to Stelara in Europe
Details : Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Product Name : Uzpruvo
Product Type : Antibody
Upfront Cash : Inapplicable
July 22, 2024
Details:
Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Brand Name: Uzpruvo
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.
Product Name : Uzpruvo
Product Type : Antibody
Upfront Cash : Inapplicable
October 11, 2023
Details:
Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Brand Name: Ximluci
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Xbrane Biopharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 16, 2023
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Xbrane Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Stada and Xbrane Obtain British Approval for Ximluci® (ranibizumab) Biosimilar Referencing Lucent...
Details : Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation...
Product Name : Ximluci
Product Type : Antibody
Upfront Cash : Inapplicable
January 16, 2023
Details:
Nefecon (budesonide) is a patented novel, investigational oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the ileum where the Peyer’s patches are concentrated.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Calliditas Therapeutics AB
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 20, 2022
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Calliditas Therapeutics AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nefecon (budesonide) is a patented novel, investigational oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the ileum where the Peyer’s patches are c...
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
September 20, 2022
Details:
The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.
Lead Product(s): Etilevodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2021
Lead Product(s) : Etilevodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
STADA Launches Novel Parkinson’s Therapy in Germany and Austria
Details : The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2021
Details:
Under the licensing agreement Bausch + Lomb will be responsible for the sales, marketing and all other commercialization efforts for Lucentis in the U.S and Canada following regulatory approval.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Brand Name: Ximluci
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Bausch & Lomb Incorporated
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 05, 2020
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the licensing agreement Bausch + Lomb will be responsible for the sales, marketing and all other commercialization efforts for Lucentis in the U.S and Canada following regulatory approval.
Product Name : Ximluci
Product Type : Antibody
Upfront Cash : Undisclosed
June 05, 2020
Regulatory Info :
Registration Country : Italy
Dosage Form : Film-Coated Tablets
Brand Name : ACECLOFENAC EG
Dosage Strength : 100 mg
Packaging : 40 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Brand Name : Aceclofenac Stada Generic...
Dosage Strength : 100 Mg/Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Brand Name : Aceclofenac Stada Generic...
Dosage Strength : 100 Mg/Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Brand Name : Aceclofenac Stada 100Mg 2...
Dosage Strength : 100 Mg/Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Brand Name : Aceclofenac Stada 100Mg 4...
Dosage Strength : 100 Mg/Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Sweden
Dosage Form : GASTRO
Brand Name : Tianzakt
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Dosage Form : Gastro-Resistant Tablets
Brand Name : ACETYLSALICYLIC ACID EG
Dosage Strength : 100 mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Dosage Form : TABLET
Brand Name : acyclovir Tablets
Dosage Strength : 800 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Dosage Form : TABLET
Brand Name : acyclovir Tablets
Dosage Strength : 200 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Dosage Form : TABLET
Brand Name : acyclovir Tablets
Dosage Strength : 400 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Dosage Strength : 100 Mg/Tablet
Packaging :
Brand Name : Aceclofenac Stada Generic 100...
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Dosage Strength : 100 Mg/Tablet
Packaging :
Brand Name : Aceclofenac Stada 100Mg 20 Co...
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Dosage Strength : 100 Mg/Tablet
Packaging :
Brand Name : Aceclofenac Stada Generic 100...
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Spain
Dosage Form : Tablet
Dosage Strength : 100 Mg/Tablet
Packaging :
Brand Name : Aceclofenac Stada 100Mg 40 Co...
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info :
Registration Country : Italy
Dosage Form : Film-Coated Tablets
Dosage Strength : 100 mg
Packaging : 40 UNITS 100 MG - ...
Brand Name : ACECLOFENAC EG
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Dosage Form : GASTRO
Dosage Strength : 100 MG
Packaging :
Brand Name : Tianzakt
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Dosage Form : Gastro-Resistant Tablets
Dosage Strength : 100 mg
Packaging : 30 UNITS 100 MG - ...
Brand Name : ACETYLSALICYLIC ACID EG
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Dosage Form : TABLET
Dosage Strength : 800 MG
Packaging :
Brand Name : acyclovir Tablets
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Dosage Form : TABLET
Dosage Strength : 400 MG
Packaging :
Brand Name : acyclovir Tablets
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Dosage Form : TABLET
Dosage Strength : 200 MG
Packaging :
Brand Name : acyclovir Tablets
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
ABOUT THIS PAGE